BioSpace News Archive

Dr. Gendreau, a seasoned industry veteran, brings to Intec Pharma over 30 years of experience in the drug development and pharmaceutical industry.

With its two-year ADCF partnership, Henry Schein will donate health care product kits valued at $5,000 each, containing gloves, gauze, gowns, and masks.

CENTOGENE announced it has surpassed more than one billion identified alleles in their global patient cohorts within its database of more than 200,000 patient samples.

Synedgen announced that research elucidating the role of complex sugars and ions and their potential role in the treatment of diseases was published in the journal, Macromolecular Theory and Simulation.

The primary objectives of the STITCH study are to assess the success of horizontal meniscus tear repair using Ceterix’s NovoStitch meniscal repair system or other suture-only techniques, and to assess improvements in knee pain and function after repair.

The claims language gives Elute broad protection for the first combination drug/device product on the market capable of delivering an antibiotic for up to eight weeks to eradicate infection and grow new bone.

The aim of Accelerate@Babraham is to support the development of science concepts and the creation of new companies by providing access to equipped communal laboratories on short-term agreements, as well as guidance from mentors and introductions to investors.

Asana BioSciences today announced that it will present the clinical proof of concept study results with ASN002, an oral, once-daily dual JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis in the late-breaking session at the annual meeting of the American Association of Dermatology in San Diego to be held February 16 - 20, 2018.

Boehringer Ingelheim announced today that Paul Fonteyne, U.S. President and CEO will retire after 15 years of committed service on December 31, 2018.

Cerus Corporation today announced the pricing of a registered underwritten public offering of its common stock for proceeds of $50.0 million, before deducting estimated offering expenses payable by Cerus.